Meihua Group has disclosed its earnings forecast, expecting net profit attributable to shareholders of 600 million to 800 million yuan for the first half of 2026, a year-on-year decline of 55% to 66%. Deducted non-recurring net profit is projected at 430 million to 630 million yuan, down 61% to 74% year-on-year. The company stated that due to factors such as increased industry supply, prices of major products including monosodium glutamate, threonine, and lysine fell year-on-year, leading to a decline in overall operating profit. The company said it will continue to advance production and cost control, accelerate the deployment of overseas markets and high-value-added products such as pharmaceutical-grade amino acids, and deepen the optimization and upgrading of production capacity structure and processes.
MeiHua Holdings Group Co LtdCompany expects net profit to fall 55%-66% due to price declines of major products (monosodium glutamate, threonine, lysine) from increased industry supply.